⚠ Evidence warning: Clinical trials or other evidence do not support the claim that black seed protects pancreatic beta cells in people and treats the root inflammatory cause of type 2 diabetes; beta-cell protection has been shown only in rodent studies, and no human trial has measured it. This page keeps it as a report of what people, websites or other media say.

Black Seed for Diabetes and Metabolic Syndrome

Diabetes and Metabolic — scientific infographic poster

The strongest human evidence for any black seed indication is in type 2 diabetes. Two key randomized controlled trials ran for 12 weeks — Bamosa et al. 2010 (Saudi Arabia, 94 patients, black seed powder in capsules at 1, 2 or 3 grams per day) and Heshmati et al. 2015 (Iran, 72 patients, 3 grams per day of black seed oil versus placebo). In the Bamosa trial, hemoglobin A1c (HbA1c) fell by 1.52 percentage points from baseline at 2 grams per day, with no further gain at 3 grams; in the Heshmati trial, HbA1c fell significantly compared with placebo. Meta-analyses pooling many trials report smaller average falls in HbA1c, from 0.44 to 0.71 percentage points. The mechanism combines AMP-activated protein kinase (AMPK) activation (mimicking metformin), direct protection of pancreatic beta cells against oxidative damage, improved insulin sensitivity at the muscle and liver, and reductions in total cholesterol, low-density lipoprotein (LDL), and triglycerides. This deep-dive walks through both trials in clinical detail, the molecular mechanism, the doses used in the trials, and the safety considerations when combining black seed with conventional diabetes medication.


Table of Contents

  1. The Bamosa 2010 Saudi Randomized Controlled Trial
  2. The Heshmati et al. 2015 Iranian Randomized Controlled Trial
  3. Meta-Analyses of Black Seed in Type 2 Diabetes
  4. Thymoquinone and Pancreatic Beta-Cell Protection
  5. AMP-Activated Protein Kinase Activation — The Metformin-Like Mechanism
  6. Insulin Sensitivity at Muscle and Liver
  7. Lipid Improvements: Cholesterol, Low-Density Lipoprotein, Triglycerides
  8. Metabolic Syndrome and Weight Trial Evidence
  9. Doses Used in the Trials
  10. Drug Interactions and Hypoglycemia Risk
  11. Key Research Papers
  12. Connections
  13. Featured Videos

The Bamosa 2010 Saudi Randomized Controlled Trial

The Bamosa et al. 2010 trial published in the Indian Journal of Physiology and Pharmacology is the foundational human study for black seed in type 2 diabetes. The trial design:

The 2 g/day dose gave the clearest result. The 1 g/day arm showed trends toward improvement that were not statistically significant from baseline, and the 3 g/day arm gave no further gain over 2 g/day. In the 2 g/day arm:

For context, the regulatory threshold for a new diabetes drug to be approved by the U.S. Food and Drug Administration (FDA) is typically a 0.5 percentage point hemoglobin A1c reduction versus placebo. The Bamosa effect size is three times that threshold.

The trial has limitations: single-blind rather than double-blind, single-center, and the patients were on background diabetes medication so the pure black-seed effect cannot be perfectly isolated. The trial also had no placebo group — it compared three doses. But the magnitude of effect at 2 g/day makes this one of the strongest human studies for any herbal hypoglycemic.

Back to Table of Contents

The Heshmati et al. 2015 Iranian Randomized Controlled Trial

The Heshmati et al. 2015 trial published in Food Research International tested black seed oil rather than seed powder:

Results:

The Heshmati design was stronger than Bamosa in two ways: it was double-blind, and it used a placebo arm rather than only dose comparisons. The finding of a significant hemoglobin A1c fall using a different form of black seed (oil vs powder), in a different population (Iranian vs Saudi), with a different design (placebo-controlled vs dose-ranging), strengthens the confidence that the effect is real and not a single-center artifact.

In this trial, blood sugar and two of the blood-fat markers (triglycerides and low-density lipoprotein) improved together compared with placebo; the high-density lipoprotein rise was not significant after adjustment, and the trial summary reports no blood-pressure result. Black seed's proposed multi-target activity at the nuclear factor kappa B (NF-kB) / AMP-activated protein kinase / lipid-metabolism node is the explanation usually offered for effects on both blood sugar and blood fats.

Back to Table of Contents

Meta-Analyses of Black Seed in Type 2 Diabetes

Several meta-analyses have pooled the available black seed diabetes trials. The 2017 meta-analysis by Daryabeygi-Khotbehsara et al. in Complementary Therapies in Medicine pooled seven trials in type 2 diabetes and found:

The pooled effect is somewhat smaller than the individual Bamosa and Heshmati trials, partly because the meta-analysis includes lower-dose trials and trials with shorter duration. But the same direction for blood sugar, hemoglobin A1c and cholesterol across seven trials, conducted in different countries and using different black seed preparations, is the meaningful signal — this is not a single-trial finding that fails to replicate.

A 2019 meta-analysis by Askari et al. in Phytotherapy Research pooled 17 randomized controlled trials on blood-sugar control. Black seed lowered fasting glucose by 9.93 mg/dL, glucose after meals by 14.79 mg/dL and hemoglobin A1c by 0.57 percentage points; black seed oil lowered fasting glucose more than black seed powder.

A 2025 meta-analysis by Karimi et al. in Complementary Therapies in Medicine pooled 16 randomized controlled trials in people with type 2 diabetes. Black seed lowered fasting glucose by 21.43 mg/dL, hemoglobin A1c by 0.44 percentage points, total cholesterol by 18.80 mg/dL and low-density lipoprotein by 19.53 mg/dL. It found no significant effect on 2-hour after-meal glucose, fasting insulin, insulin resistance (HOMA), triglycerides, high-density lipoprotein, the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT), creatinine (a kidney marker), body weight or body mass index. In its subgroup analyses, the fasting-glucose fall was seen in trials longer than 8 weeks, and the falls in hemoglobin A1c, HOMA and low-density lipoprotein in trials using more than 1 g/day, trials of 8 weeks or less, and trials using the oil.

Back to Table of Contents

Thymoquinone and Pancreatic Beta-Cell Protection

Type 2 diabetes is characterized by both insulin resistance (peripheral tissues do not respond properly to insulin) and progressive pancreatic beta-cell failure (the cells that produce insulin gradually die off, partly from oxidative stress and partly from glucotoxicity). Most diabetes medications address insulin resistance (metformin, thiazolidinediones) or stimulate residual beta-cell function (sulfonylureas, glucagon-like peptide-1 (GLP-1) agonists). Few medications meaningfully protect the beta cells from ongoing damage.

Thymoquinone has shown striking beta-cell protective effects in animal models. In the classic streptozotocin (STZ) and alloxan diabetic-rat models — in which a single high dose of STZ or alloxan selectively destroys pancreatic beta cells via oxidative damage and produces diabetes within days — pretreatment with thymoquinone partially blocks beta-cell destruction. Histology of pancreatic islets in thymoquinone-pretreated rats shows preserved islet architecture and substantially higher beta-cell mass compared to untreated diabetic controls.

The mechanism involves several converging effects:

  1. Direct antioxidant activity — thymoquinone is a quinone with significant free-radical scavenging activity, particularly against the superoxide and hydroxyl radicals generated by STZ/alloxan metabolism in beta cells
  2. Mitochondrial protection — thymoquinone preserves mitochondrial membrane potential and prevents the mitochondrial permeability transition that triggers beta-cell apoptosis
  3. Anti-apoptotic signaling — thymoquinone upregulates Bcl-2 and downregulates Bax in beta cells, shifting the apoptosis/survival balance toward survival
  4. Suppression of NF-kB-driven inflammatory beta-cell damage — chronic low-grade pancreatic inflammation contributes to type 2 diabetes progression; thymoquinone's NF-kB inhibition addresses this

The human translation is necessarily indirect — we cannot biopsy human pancreatic islets to measure beta-cell mass in living patients — but in the Bamosa trial, beta-cell function calculated from blood tests (HOMA2) rose from baseline at 2 g/day (P<0.02) after 12 weeks; that trial had no placebo group, so it cannot show that black seed users keep beta-cell function better than people not taking it. This is a potentially distinctive benefit of black seed compared to most other diabetes interventions, which tend to either work the beta cells harder (sulfonylureas, accelerating burnout) or merely improve insulin response without addressing beta-cell preservation.

Back to Table of Contents

AMP-Activated Protein Kinase Activation — The Metformin-Like Mechanism

Metformin, the first-line oral medication for type 2 diabetes worldwide, works primarily by activating AMP-activated protein kinase (AMPK) in the liver. AMP-activated protein kinase is the cellular energy sensor — when cellular adenosine triphosphate (ATP) levels fall (signaling low energy), AMP-activated protein kinase activates a cascade of responses that increases adenosine triphosphate-generating processes (fatty acid oxidation, glucose uptake) and suppresses adenosine triphosphate-consuming processes (gluconeogenesis, fatty acid synthesis, cholesterol synthesis).

Thymoquinone activates AMP-activated protein kinase through a mechanism distinct from but parallel to metformin. The downstream effects on glucose metabolism are similar:

The clinical practical implication is that black seed and metformin appear to have additive rather than redundant glycemic effects in trial settings — patients on metformin who add black seed still see additional hemoglobin A1c reduction. The mechanisms overlap but the molecular targets are sufficiently distinct that the effects sum rather than max out. In the Bamosa trial, black seed was added to patients' existing diabetes medicines and hemoglobin A1c fell 1.52 percentage points from baseline at 2 g/day; with no placebo group, that trial cannot separate the black seed effect from other changes over the 12 weeks.

For people who cannot tolerate metformin (the gastrointestinal side effects are dose-limiting for 10–15% of users) or who have advanced renal disease that contraindicates metformin (estimated glomerular filtration rate (eGFR) < 30): none of the trials described on this page enrolled people with advanced kidney disease, and a 2013 case report described acute kidney failure in a diabetic patient taking black seed.

Back to Table of Contents

Insulin Sensitivity at Muscle and Liver

Beyond the AMP-activated protein kinase pathway, black seed appears to improve insulin signaling in skeletal muscle and liver through additional mechanisms. Animal studies have shown:

The tumor necrosis factor-alpha and interleukin-6 connection is particularly interesting because obesity-driven type 2 diabetes is increasingly understood as an inflammatory condition — chronic low-grade inflammation in adipose tissue and liver drives insulin resistance, which drives compensatory hyperinsulinemia, which over years drives beta-cell failure. By reducing the inflammatory signal at the source (NF-kB inhibition), black seed addresses the root inflammatory driver of type 2 diabetes, not just the downstream glucose elevation.

This is also why black seed's benefit is especially pronounced in patients with the obese, metabolic-syndrome phenotype of type 2 diabetes rather than in lean autoimmune-like type 2 diabetes or LADA (latent autoimmune diabetes in adults). For more on metabolic-syndrome-driven type 2 diabetes, see Insulin Resistance and Diabetes.

Back to Table of Contents

Lipid Improvements: Cholesterol, Low-Density Lipoprotein, Triglycerides

Black seed trials have measured blood fats alongside blood sugar. The Heshmati trial showed:

A 2016 meta-analysis by Sahebkar et al. pooled 17 randomized placebo-controlled trials of black seed and blood fats. Black seed lowered total cholesterol by 15.65 mg/dL, low-density lipoprotein by 14.10 mg/dL and triglycerides by 20.64 mg/dL, with no significant overall effect on high-density lipoprotein (0.28 mg/dL). Black seed oil lowered total cholesterol and low-density lipoprotein more than the seed powder, and a rise in high-density lipoprotein was found only with the seed powder.

The mechanism is multi-faceted:

For a person with combined metabolic syndrome (type 2 diabetes + dyslipidemia + hypertension), the pooled trials above report effects on two of the three components, blood sugar and blood fats. The size of each effect is smaller than with dedicated single-agent therapy (a full-dose statin reduces low-density lipoprotein by 40–60%).

Back to Table of Contents

Metabolic Syndrome and Weight Trial Evidence

Beyond strict type 2 diabetes, black seed has been studied in metabolic syndrome (the cluster of central obesity + dyslipidemia + hypertension + insulin resistance / hyperglycemia that precedes overt type 2 diabetes). The Mahdavi trial in obese women (90 enrolled, 84 completed; 8 weeks of black seed oil 3 g/day or placebo, with both groups on a low-calorie diet) showed, compared with placebo:

The weight loss is modest in absolute terms, and it came on top of a low-calorie diet that both groups followed, so the trial tested black seed as an addition to diet rather than on its own.

For the broader metabolic-syndrome management framework, see Metabolic Syndrome and Blood Sugar Management.

Back to Table of Contents

Doses Used in the Trials

The doses and forms used in the trials described on this page:

Back to Table of Contents

Drug Interactions and Hypoglycemia Risk

The good news: in the clinical trials, no serious adverse events have been reported at the doses used. The interactions above are manageable with awareness and appropriate monitoring. Black seed is one of the better-tolerated herbal interventions in diabetes care, with substantially fewer side effects than metformin (no gastrointestinal intolerance), sulfonylureas (hypoglycemia, weight gain), or thiazolidinediones (fluid retention, fracture risk).

Back to Table of Contents

Key Research Papers

  1. Bamosa AO et al. (2010). Effect of Nigella sativa seeds on the glycemic control of patients with type 2 diabetes mellitus. Indian Journal of Physiology and Pharmacology. — PubMed PMID: 21675032
  2. Heshmati J, Namazi N, Memarzadeh MR, Taghizadeh M, Kolahdooz F (2015). Nigella sativa oil affects glucose metabolism and lipid concentrations in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Food Research International, 70, 87–93. — doi:10.1016/j.foodres.2015.01.030
  3. Daryabeygi-Khotbehsara R et al. (2017). Nigella sativa improves glucose homeostasis and serum lipids in type 2 diabetes: A systematic review and meta-analysis. Complementary Therapies in Medicine. — PubMed PMID: 29154069
  4. Askari G, Rouhani MH, Ghaedi E, Ghavami A, Nouri M, Mohammadi H (2019). Effect of Nigella sativa (black seed) supplementation on glycemic control: A systematic review and meta-analysis of clinical trials. Phytotherapy Research. — PubMed PMID: 30873688
  5. Karimi M, Pirzad S, Pourfaraji SMA, Sedgi FM, Darouei B, Amani-Beni R, Kazemi K, Rabiee R (2025). Effects of black seed (Nigella sativa L.) on cardiometabolic indices in type 2 diabetic patients: A systematic review and meta-analysis of RCTs. Complementary Therapies in Medicine. — PubMed PMID: 40210172
  6. Mahdavi R et al. (2015). Effects of Nigella sativa oil with a low-calorie diet on cardiometabolic risk factors in obese women: a randomized controlled clinical trial. Food & Function. — PubMed PMID: 26029855
  7. Kanter M, Coskun O, Korkmaz A, Oter S (2004). Effects of Nigella sativa on oxidative stress and beta-cell damage in streptozotocin-induced diabetic rats. Anatomical Record Part A. — PubMed PMID: 15224410
  8. El-Mahmoudy A et al. (2005). Successful abrogation by thymoquinone against induction of diabetes mellitus with streptozotocin via nitric oxide inhibitory mechanism. International Immunopharmacology. — PubMed PMID: 15589481
  9. Najmi A, Nasiruddin M, Khan RA, Haque SF (2008). Effect of Nigella sativa oil on various clinical and biochemical parameters of insulin resistance syndrome. International Journal of Diabetes in Developing Countries. — PubMed PMID: 19902033
  10. Sahebkar A et al. (2016). Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological Research. — PubMed PMID: 26875640
  11. Benhaddou-Andaloussi A et al. (2011). The in vivo antidiabetic activity of Nigella sativa is mediated through activation of the AMPK pathway and increased muscle Glut4 content. Evidence-Based Complementary and Alternative Medicine. — PubMed PMID: 21584245
  12. Fararh KM, Atoji Y, Shimizu Y, Takewaki T (2002). Isulinotropic properties of Nigella sativa oil in Streptozotocin plus Nicotinamide diabetic hamster. Research in Veterinary Science. — PubMed PMID: 12443686
  13. Razavi BM, Hosseinzadeh H (2014). A review of the effects of Nigella sativa L. and its constituent, thymoquinone, in metabolic syndrome. Journal of Endocrinological Investigation. — PubMed PMID: 25125023
  14. Arslan E, Sayin S, Demirbas S, Cakar M, Somak NG, Yesilkaya S, Saglam K (2013). A case study report of acute renal failure associated with Nigella sativa in a diabetic patient. Journal of Integrative Medicine. — PubMed PMID: 23464648

PubMed Topic Searches

  1. PubMed: Nigella sativa type 2 diabetes HbA1c
  2. PubMed: Thymoquinone pancreatic beta cell
  3. PubMed: Nigella sativa AMPK / insulin
  4. PubMed: Nigella sativa lipid meta-analysis
  5. PubMed: Nigella sativa metabolic syndrome / obesity

Back to Table of Contents

Connections

Back to Table of Contents